Record entry · Auto
Presidential Symposium
What is happening now
Cannot measure: the record's node for this name could not be read, so its claims are not known here.
How well we know this
Cannot measure: No entity labelled "presidential-symposium" in the record at 2026-11-03T13:08:56.552092+00:00. Try search_entities, or GET /api/signals..
Why this name is on the record
Presidential Symposium was added automatically on 3 Nov 2026 after 20 mentions across 8 sources over 11 days. 75% of that coverage came from a single subject area.
The counts themselves: counted automatically from tracked coverage on 3 Nov 2026
Reported alongside Presidential Symposium
The neighbourhood is not yet read for this page.
For developers
GET https://api.signalbureau.ai/api/registry?slug=presidential-symposium
{
"slug": "presidential-symposium",
"state": "active",
"detail": {
"state": "active",
"source": "ontology",
"label": "presidential symposium",
"promotedAt": "2026-11-03",
"category": "auto",
"evidence": {
"mentions": 20,
"sources": 8,
"days": 11,
"concentration": 0.75,
"standAloneShare": 0.864
}
}
}The record behind this page, as data. The live response also carries the registry date and version.
Walk the record from Presidential Symposium
This name is not in the walkable record yet: the entity graph does not carry it at this cutoff.
The coverage behind it
- 1 Nov 2026
European Medical Journal
Targeted ADC Delays Progression in Relapsed Osteosarcoma: ESMO 2026 (opens the original article)
- 29 Oct 2026
Clinical Trials Arena
Podcast: ESMO26: Major readouts from the 2026 congress (opens the original article)
- 27 Oct 2026
Clinical Trials Arena
ESMO26: Other skin cancer advances beyond groundbreaking cancer vaccine (opens the original article)
- 26 Oct 2026
Clinical Trials Arena
ESMO26: Combination therapies show promise in prostate cancer (opens the original article)
- 30 Sept 2026
The ASCO Post
Targeting B7-H3 in Second-Line SCLC Treatment Novel ADCs (opens the original article)
- 22 Sept 2026
The Clinical Trial Vanguard
Ivonescimab beats durvalumab in biliary tract cancer Phase III trial (opens the original article)
No trend and no market price are shown because neither has been measured for Presidential Symposium yet. Informational only, not advice. As of 3 Nov 2026.